Richard Moss

List of Publications by Year
in descending order

149 papers	15,741 citations	23567 58 h-index	16650 123 g-index
153 all docs	153 docs citations	153 times ranked	9915 citing authors

#	Article	IF	Citations
1	A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation. New England Journal of Medicine, 2011, 365, 1663-1672.	27.0	1,920
2	Lumacaftorâ€"Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR. New England Journal of Medicine, 2015, 373, 220-231.	27.0	1,308
3	Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutation. New England Journal of Medicine, 2010, 363, 1991-2003.	27.0	741
4	Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clinical and Experimental Allergy, 2013, 43, 850-873.	2.9	666
5	Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosisâ€"State of the Art: Cystic Fibrosis Foundation Consensus Conference. Clinical Infectious Diseases, 2003, 37, S225-S264.	5.8	658
6	Late Pulmonary Sequelae of Bronchopulmonary Dysplasia. New England Journal of Medicine, 1990, 323, 1793-1799.	27.0	515
7	Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for theF508del-CFTRmutation. Thorax, 2012, 67, 12-18.	5.6	466
8	Fungi and allergic lower respiratory tract diseases. Journal of Allergy and Clinical Immunology, 2012, 129, 280-291.	2.9	398
9	A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respiratory Medicine,the, 2014, 2, 527-538.	10.7	372
10	Repeated Adeno-Associated Virus Serotype 2 Aerosol-Mediated Cystic Fibrosis Transmembrane Regulator Gene Transfer to the Lungs of Patients With Cystic Fibrosis. Chest, 2004, 125, 509-521.	0.8	351
11	Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2014, 2, 539-547.	10.7	301
12	Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 841-849.	5.6	300
13	A Phase II, Double-Blind, Randomized, Placebo-Controlled Clinical Trial of tgAAVCF Using Maxillary Sinus Delivery in Patients with Cystic Fibrosis with Antrostomies. Human Gene Therapy, 2002, 13, 1349-1359.	2.7	239
14	Repeated Aerosolized AAV-CFTR for Treatment of Cystic Fibrosis: A Randomized Placebo-Controlled Phase 2B Trial. Human Gene Therapy, 2007, 18, 726-732.	2.7	239
15	High-dose oral N -acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4628-4633.	7.1	235
16	Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respiratory Medicine,the, 2017, 5, 107-118.	10.7	235
17	Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet, The, 1998, 351, 1702-1703.	13.7	220
18	A Phase I Study of Aerosolized Administration of tgAAVCF to Cystic Fibrosis Subjects with Mild Lung Disease. Human Gene Therapy, 2001, 12, 1907-1916.	2.7	219

#	Article	IF	Citations
19	Comparative Efficacy and Safety of 4 Randomized Regimens to Treat EarlyPseudomonas aeruginosaInfection in Children With Cystic Fibrosis. JAMA Pediatrics, 2011, 165, 847.	3.0	199
20	Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respiratory Medicine,the, 2015, 3, 524-533.	10.7	197
21	Safety and Biological Efficacy of an Adeno-Associated Virus Vector-Cystic Fibrosis Transmembrane Regulator (AAV-CFTR) in the Cystic Fibrosis Maxillary Sinus. Laryngoscope, 1999, 109, 266-274.	2.0	193
22	Seasonal asthma in northern California: Allergic causes and efficacy of immunotherapy. Journal of Allergy and Clinical Immunology, 1986, 78, 590-600.	2.9	182
23	Long-term Benefits of Inhaled Tobramycin in Adolescent Patients With Cystic Fibrosis. Chest, 2002, 121, 55-63.	0.8	158
24	Cow's milk allergy in breast-fed infants: The role of allergen and maternal secretory IgA antibody. Journal of Allergy and Clinical Immunology, 1986, 77, 341-347.	2.9	153
25	Bone acquisition and loss in children and adults with cystic fibrosis: A longitudinal study. Journal of Pediatrics, 1998, 133, 18-27.	1.8	148
26	Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. Journal of Pediatrics, 1988, 112, 547-554.	1.8	143
27	Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis. Chest, 1999, 115, 364-370.	0.8	143
28	Osteopenia in adults with cystic fibrosis. American Journal of Medicine, 1994, 96, 27-34.	1.5	141
29	Sputum Cathelicidin, Urokinase Plasminogen Activation System Components, and Cytokines Discriminate Cystic Fibrosis, COPD, and Asthma Inflammation. Chest, 2005, 128, 2316-2326.	0.8	140
30	Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4335-4339.	7.1	126
31	Comparison of a Î²-lactam alone versus Î²-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics, 1999, 134, 413-421.	1.8	124
32	Grass pollen immunotherapy: A single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. Journal of Allergy and Clinical Immunology, 1984, 73, 283-290.	2.9	112
33	Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clinical and Experimental Immunology, 2000, 120, 518-525.	2.6	107
34	Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2013, 12, 241-248.	0.7	102
35	Dornase Alfa Reduces Air Trapping in Children With Mild Cystic Fibrosis Lung Disease. Chest, 2005, 128, 2327-2335.	0.8	96
36	A Phase I/II Study of tgAAV-CF for the Treatment of Chronic Sinusitis in Patients with Cystic Fibrosis. Stanford University, Stanford, California. Human Gene Therapy, 1998, 9, 889-909.	2.7	95

#	Article	IF	Citations
37	A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis. Human Molecular Genetics, 1998, 7, 729-735.	2.9	92
38	Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5779-5783.	7.1	90
39	Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. Journal of Cystic Fibrosis, 2015, 14, 219-227.	0.7	90
40	Pulmonary Sequelae of Bronchopulmonary Dysplasia Survivors. American Journal of Roentgenology, 2000, 174, 1323-1326.	2.2	88
41	Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatric Pulmonology, 2007, 42, 610-623.	2.0	88
42	Long term effects of denufosol tetrasodium in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 539-549.	0.7	85
43	Administration of Aerosolized Antibiotics in Cystic Fibrosis Patients. Chest, 2001, 120, 107S-113S.	0.8	84
44	Sinus disease in patients with severe cystic fibrosis: relation to pulmonary exacerbation. Lancet, The, 1990, 335, 1077-1078.	13.7	82
45	Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis. European Respiratory Journal, 2014, 43, 1487-1500.	6.7	82
46	Earth Moverâ€™s Distance (EMD): A True Metric for Comparing Biomarker Expression Levels in Cell Populations. PLoS ONE, 2016, 11, e0151859.	2.5	82
47	Allergy to semisynthetic penicillins in cystic fibrosis. Journal of Pediatrics, 1984, 104, 460-466.	1.8	81
48	No Detectable Improvements in Cystic Fibrosis Transmembrane Conductance Regulator by Nasal Aminoglycosides in Patients with Cystic Fibrosis with Stop Mutations. American Journal of Respiratory Cell and Molecular Biology, 2007, 37, 57-66.	2.9	81
49	Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clinical and Experimental Immunology, 1996, 106, 374-388.	2.6	80
50	Composite Spirometricâ€“Computed Tomography Outcome Measure in Early Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 588-593.	5.6	78
51	Pathophysiology and immunology of allergic bronchopulmonary aspergillosis. Medical Mycology, 2005, 43, 203-206.	0.7	78
52	Inhibition of Aspergillus fumigatus and Its Biofilm by Pseudomonas aeruginosa Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium. PLoS ONE, 2015, 10, e0134692.	2.5	77
53	Quantitative air-trapping analysis in children with mild cystic fibrosis lung disease. Pediatric Pulmonology, 2004, 38, 396-405.	2.0	73
54	Spirometer-triggered high-resolution computed tomography and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis. Journal of Pediatrics, 2001, 138, 553-559.	1.8	71

#	Article	IF	Citations
55	Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2010, 16, 598-603.	2.6	71
56	Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 627-634.	5.6	71
57	Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations.. American Journal of Respiratory and Critical Care Medicine, 1996, 153, 1914-1917.	5.6	67
58	Suppression of the late cutaneous response by immunotherapy1. Journal of Allergy and Clinical Immunology, 1989, 83, 101-109.	2.9	61
59	Safety, Tolerability, and Efficacy of High-Frequency Chest Wall Oscillation in Pediatric Patients With Cerebral Palsy and Neuromuscular Diseases: An Exploratory Randomized Controlled Trial. Journal of Child Neurology, 2010, 25, 815-821.	1.4	59
60	Constipation and meconium ileus equivalent in patients with cystic fibrosis. Pediatrics, 1986, 78, 473-9.	2.1	58
61	Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study of Aerosolized Interferon Gamma-1b in Patients With Mild to Moderate Cystic Fibrosis Lung Disease. Pediatric Pulmonology, 2005, 39, 209-218.	2.0	55
62	Allergic Bronchopulmonary Aspergillosis. Journal of Fungi (Basel, Switzerland), 2016, 2, 17.	3.5	55
63	Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis. Journal of Allergy and Clinical Immunology, 1991, 87, 78-88.	2.9	54
64	Deficiency of IgG4 in children: Association of isolated IgG4 deficiency with recurrent respiratory tract infection. Journal of Pediatrics, 1992, 120, 16-21.	1.8	52
65	Immune complexes and humoral response to Pseudomonas aeruginosa in cystic fibrosis. The American Review of Respiratory Disease, 1980, 121, 23-9.	2.9	52
66	Baseline Characteristics and Factors Associated With Nutritional and Pulmonary Status at Enrollment in the Cystic Fibrosis EPIC Observational Cohort. Pediatric Pulmonology, 2010, 45, 934-944.	2.0	51
67	Altered Antibody Isotype in Cystic Fibrosis. Possible Role in Opsonic Deficiency. Pediatric Research, 1986, 20, 453-459.	2.3	49
68	A Little CFTR Goes a Long Way: CFTR-Dependent Sweat Secretion from G551D and R117H-5T Cystic Fibrosis Subjects Taking Ivacaftor. PLoS ONE, 2014, 9, e88564.	2.5	49
69	Molecular epidemiology of Aspergillus collected from cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 474-481.	0.7	48
70	The basophil surface marker CD203c identifies Aspergillus species sensitization in patients with cystic fibrosis. Journal of Allergy and Clinical Immunology, 2016, 137, 436-443.e9.	2.9	47
71	Specific antibodies to recombinant allergens of Aspergillus fumigatus in cystic fibrosis patients with ABPA. Clinical and Molecular Allergy, 2006, 4, 11.	1.8	45
72	Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation. PLoS ONE, 2013, 8, e66955.	2.5	44

#	Article	IF	Citations
73	Isotypic and antigenic restriction of the blocking antibody response to ryegrass pollen: Correlation of rye group I antigen-specific IgG1 with clinical response. Journal of Allergy and Clinical Immunology, 1987, 79, 387-398.	2.9	43
74	Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis. Pediatric Pulmonology, 1990, 9, 7-18.	2.0	42
75	Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis. Current Opinion in Pediatrics, 2018, 30, 372-377.	2.0	42
76	125I-Clq-binding and specific antibodies as indicators of pulmonary disease activity in cystic fibrosis. Journal of Pediatrics, 1981, 99, 215-222.	1.8	41
77	Diagnostic Testing by CFTR Gene Mutation Analysis in a Large Group of Hispanics. Journal of Molecular Diagnostics, 2005, 7, 289-299.	2.8	40
78	Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens. Journal of Cystic Fibrosis, 2012, 11, 502-510.	0.7	40
79	Pitfalls of Drug Development: Lessons Learned from Trials of Denufosol in Cystic Fibrosis. Journal of Pediatrics, 2013, 162, 676-680.	1.8	40
80	Safety and Preliminary Clinical Activity of a Novel Pancreatic Enzyme Preparation in Pancreatic Insufficient Cystic Fibrosis Patients. Pancreas, 2006, 32, 258-263.	1.1	39
81	Sputum Tobramycin Concentrations in Cystic Fibrosis Patients with Repeated Administration of Inhaled Tobramycin. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2013, 26, 69-75.	1.4	39
82	Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis. European Respiratory Journal, 2016, 47, 177-185.	6.7	39
83	The myriad challenges of respiratory fungal infection in cystic fibrosis. Pediatric Pulmonology, 2018, 53, S75-S85.	2.0	39
84	Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.. Journal of Clinical Investigation, 1989, 84, 1794-1804.	8.2	37
85	Socioeconomic Status and the Likelihood of Antibiotic Treatment for Signs and Symptoms of Pulmonary Exacerbation in Children with Cystic Fibrosis. Journal of Pediatrics, 2011, 159, 819-824.e1.	1.8	36
86	Anti-arthropod saliva antibodies among residents of a community at high risk for Lyme disease in California.. American Journal of Tropical Medicine and Hygiene, 1999, 61, 850-859.	1.4	36
87	Altered Antibody Isotype in Cystic Fibrosis: Impaired Natural Antibody Response to Polysaccharide Antigens. Pediatric Research, 1987, 22, 708-713.	2.3	33
88	Two novel mutations in a cystic fibrosis patient of Chinese origin. Human Genetics, 1999, 104, 511-515.	3.8	33
89	Fungi in Cystic Fibrosis and Nonâ€“Cystic Fibrosis Bronchiectasis. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 207-216.	2.1	32
90	Comprehensive Mutation Screening in a Cystic Fibrosis Center. Pediatrics, 2001, 107, 280-286.	2.1	28

#	Article	IF	Citations
91	Cystic fibrosis HRCT scores correlate strongly with pseudomonas infection. Pediatric Pulmonology, 2009, 44, 1107-1117.	2.0	27
92	Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials in patients with antrostomies. Journal of Gene Medicine, 1999, 1, 13-21.	2.8	27
93	Hypergammaglobulinemia in Cystic Fibrosis. Chest, 1987, 91, 522-526.	0.8	26
94	Fully Automated System for Three-Dimensional Bronchial Morphology Analysis Using Volumetric Multidetector Computed Tomography of the Chest. Journal of Digital Imaging, 2006, 19, 132-139.	2.9	26
95	The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis. Annals of the New York Academy of Sciences, 2012, 1272, 49-57.	3.8	26
96	Underestimation of specific immunoglobulin E by microtiter plate enzyme-linked immunosorbent assays. Journal of Allergy and Clinical Immunology, 1985, 76, 172-176.	2.9	25
97	Alternative Pharmacotherapies for Steroid-Dependent Asthma. Chest, 1995, 107, 817-825.	0.8	24
98	Stevens et al. (2003;â€‰37[Suppl 3]:S225â€“64). Clinical Infectious Diseases, 2004, 38, 158-158.	5.8	24
99	Interobserver Variance in Clinical Scoring for Cystic Fibrosis. Chest, 1987, 91, 878-882.	0.8	22
100	Reproducibility of skin prick testing with allergen extracts from different manufacturers. Allergy: European Journal of Allergy and Clinical Immunology, 1988, 43, 458-463.	5.7	21
101	IgE antibodies in tick bite-induced anaphylaxis. Journal of Allergy and Clinical Immunology, 1991, 88, 968-970.	2.9	20
102	Advances against Aspergillosis. Clinical Infectious Diseases, 2003, 37, S155-S156.	5.8	20
103	Lymphocytes in cystic fibrosis lung disease: a tale of two immunities. Clinical and Experimental Immunology, 2004, 135, 358-360.	2.6	20
104	Critique of trials in allergic bronchopulmonary aspergillosis and fungal allergy. Medical Mycology, 2006, 44, S269-S272.	0.7	20
105	Resistin is elevated in cystic fibrosis sputum and correlates negatively with lung function. Journal of Cystic Fibrosis, 2019, 18, 64-70.	0.7	20
106	Highlights of a workshop to discuss targeting inflammation in cystic fibrosis. Journal of Cystic Fibrosis, 2009, 8, 1-8.	0.7	18
107	Small Colony Variants of Pseudomonas aeruginosa Display Heterogeneity in Inhibiting Aspergillus fumigatus Biofilm. Mycopathologia, 2018, 183, 263-272.	3.1	18
108	Treating allergic bronchopulmonary aspergillosis: the way forward. European Respiratory Journal, 2016, 47, 385-387.	6.7	17

#	Article	IF	Citations
109	Supraventricular Tachycardia in Patients with Cystic Fibrosis. Chest, 1986, 90, 239-242.	0.8	16
110	Activation of Eosinophils in the Airways of Lung Transplantation Patients. Chest, 1997, 112, 1180-1183.	0.8	16
111	Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center. Antimicrobial Agents and Chemotherapy, 2016, 60, 2180-2184.	3.2	16
112	Mucus plugging, air trapping, and bronchiectasis are important outcome measures in assessing progressive childhood cystic fibrosis lung disease. Pediatric Pulmonology, 2020, 55, 929-938.	2.0	16
113	Biomarkers for the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis: A Systematic Review and Meta-Analysis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1909-1930.e4.	3.8	15
114	Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation. Journal of Cystic Fibrosis, 2018, 17, 503-510.	0.7	14
115	Are Cystic Fibrosis Aspergillus fumigatus Isolates Different? Intermicrobial Interactions with Pseudomonas. Mycopathologia, 2017, 182, 315-318.	3.1	13
116	Infection, Inflammation, and the Downward Spiral of Cystic Fibrosis Lung Disease. Journal of Pediatrics, 2009, 154, 162-163.	1.8	10
117	Clinician variability in the diagnosis and treatment of aspergillus fumigatus-related conditions in cystic fibrosis: An international survey. Journal of Cystic Fibrosis, 2022, 21, 136-142.	0.7	10
118	Manifestations of pulmonary aspergillosis in pediatrics. Current Opinion in Pediatrics, 2020, 32, 389-394.	2.0	10
119	Recent advances in cystic fibrosis. Current Opinion in Pediatrics, 2015, 27, 317-324.	2.0	8
120	Effect of total lymphoid irradiation on IgE antibody responses in rheumatoid arthritis and systemic lupus erythematosus. Journal of Allergy and Clinical Immunology, 1987, 80, 798-802.	2.9	7
121	Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults. Scientific Reports, 2018, 8, 16233.	3.3	7
122	Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations. Pulmonary Therapy, 2020, 6, 303-313.	2.2	7
123	The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurements. PLoS ONE, 2017, 12, e0175486.	2.5	7
124	Current treatment options for invasive aspergillosis. Drugs of Today, 2013, 49, 213.	1.1	6
125	Basophil activation test determination of CD63 combined with CD203c is not superior to CD203c alone in identifying allergic bronchopulmonary aspergillosis in cystic fibrosis. Journal of Allergy and Clinical Immunology, 2016, 138, 1195-1196.	2.9	6
126	124 Grass pollen immunotherapy, clinical and immunologic effects in a double-blind placebo-controlled study. Journal of Allergy and Clinical Immunology, 1983, 71, 119.	2.9	5

#	Article	IF	Citations
127	Novel cystic fibrosis mutation L1093P: Functional analysis and possible Native American origin. Human Mutation, 2000, 15, 208-208.	2.5	5
128	Diagnosing allergic bronchopulmonary aspergillosis/mycosis: Return to lost horizons. Journal of Allergy and Clinical Immunology, 2021, 147, 1212-1214.	2.9	5
129	Management of allergic aspergillosis. Current Fungal Infection Reports, 2008, 2, 87-93.	2.6	4
130	Mucosal humoral immunity in cystic fibrosis - a tangled web of failed proteostasis, infection and adaptive immunity. EBioMedicine, 2020, 60, 103035.	6.1	4
131	Immunoglobulin E antibodies in young children with possible allergic symptoms. Journal of Pediatrics, 1987, 110, 738-740.	1.8	3
132	Management of allergic aspergillosis. Current Allergy and Asthma Reports, 2008, 8, 433-439.	5.3	3
133	Novel contributions to the Asian CFTR mutation spectrum: Genotype and phenotype in Thai patients with cystic fibrosis. American Journal of Medical Genetics, Part A, 2005, 133A, 103-105.	1.2	2
134	Early Aspergillosis in Cystic Fibrosis and Air Trapping: Guilt by Association?. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 644-645.	5.6	2
135	37 Infantile allergy and milk-specific antibodies in breast milk. Journal of Allergy and Clinical Immunology, 1983, 71, 98.	2.9	1
136	493 Suppression of the Late Cutaneous Response (LCR) by immunotherapy (IT). Journal of Allergy and Clinical Immunology, 1988, 81, 291.	2.9	1
137	A PILOT STUDY OF POLYSOMNOGRAPHY TO EVALUATE EFFECTIVENESS OF AIRWAY CLEARANCE THERAPIES IN PEDIATRIC PATIENTS WITH CEREBRAL PALSY AND NEUROMUSCULAR DISORDERS. Chest, 2007, 132, 609A.	0.8	1
138	Basophil Activation Is a Reliable Biomarker Of Allergic Bronchopulmonary Aspergillosis (ABPA) In CF: One Year Results Of a Longitudinal Cohort Study. Journal of Allergy and Clinical Immunology, 2014, 133, AB58.	2.9	1
139	Modulatory Effects of Aspergillus Colonization and Abpa on Blood and Sputum Granulocytes in CF. Journal of Allergy and Clinical Immunology, 2016, 137, AB29.	2.9	1
140	Susceptibility of Candida albicans from Cystic Fibrosis Patients. Mycopathologia, 2017, 182, 863-867.	3.1	1
141	P255â€...Rate of lung function decline in patients with cystic fibrosis (cf) having a residual function gene mutation. , 2017, , .		1
142	Spirometer-Triggered High Resolution Computed Tomography (HRCT) of the Chest, Clinical Score, and Pulmonary Function Measurements in Cystic Fibrosis (CF) Patients before and after Treatment for a Pulmonary Exacerbation. Pediatric Research, 1999, 45, 355A-355A.	2.3	1
143	8 Once a day theophylline (uniphyl) for treatment of patients with asthma (AS) and cystic fibrosis(CF). Journal of Allergy and Clinical Immunology, 1985, 75, 106.	2.9	0
144	282 A quantitative immunoenzymatic assay for grass pollen-specific IgG antibodies. Journal of Allergy and Clinical Immunology, 1985, 75, 175.	2.9	0

#	Article	IF	Citations
145	486 Defective antibody-mediated opsonization of pseudomonas aeruginosa (PA) in cystic fibrosis (CF): An isotype-dependent deffect?. Journal of Allergy and Clinical Immunology, 1988, 81, 289.	2.9	0
146	Vocal Cord Dysfunction Syndrome and â€œSteroid-Dependentâ€•Asthmatics. Chest, 1995, 108, 1772-1773.	0.8	0
147	Clinical protocol: AAV-CFTR for the treatment of chronic sinusitis in CF patients.. Clinical Pharmacology and Therapeutics, 1996, 59, 174-174.	4.7	0
148	Study Of Sublingual Immunotherapy In Subjects With Dermatophagoides Farniae And Timothy Grass Allergy. Journal of Allergy and Clinical Immunology, 2009, 123, S126-S126.	2.9	0
149	Specific Induction Of CD203c Expression In Blood Basophils Discriminates Between CF patients With Aspergillus Colonization And Those With CF-ABPA. Journal of Allergy and Clinical Immunology, 2012, 129, AB139.	2.9	0